Advanced Medicine Partners, a Durham, NC-based developer of innovative advanced medicines, received an additional $32m in financing.
The round was led by Deerfield Management, with additional support from ARCH Venture Partners and other investors. Upon completion of this latest financing round, the total direct investment in Advanced Medicine Partners since its separation from Jaguar Gene Therapy will reach $60m.
Advanced Medicine Partners is an organization that delivers process development, manufacturing, analytical development and testing for advanced therapy products with a specialty in viral vectors for gene and cell therapies. The company uses its expertise to produce best-in-class advanced therapy products and analytics with a specialty in viral vectors for gene and cell therapies.
The company also announced the appointments of Ray Kaczmarek and Felix Hsu to the company’s Board of Directors. Mr. Kaczmarek will serve as Executive Chairman. Existing members of the Board include Jonathan Leff, Partner at Deerfield Management Company and Chairman of the Deerfield Institute; Elise Wang, Partner and Head of Private Equity Capital Markets at Deerfield Management Company; David Greenwald, Ph.D., Vice President of Business Development at Deerfield Management Company; and Andrew Knudten, CEO of Advanced Medicine Partners.
FinSMEs
05/06/2024